Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- Clinical Trial1
- Randomized Controlled Trial1
- Clinical Study1
- Comparative Study1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Cancer1
Search Results
Sort by
- Bookedited by S Paige Hertweck, Maggie L. Dwiggins.Summary: Published in association with NASPAG, this updated second edition gives quick access to the essential information. The authors combine their clinical experience with a complete review of the literature, placing it in an easy to consult format with photographs, figures, and algorithms.*Offers a concise guide to the clinical essentials in diagnosis and management for Pediatric & Adolescent Gynecology *Provides an invaluable quick reference for family physicians, nurses, residents, and trainees *Presents the clinical expertise of NASPAG expertsDigital Access TandFonline 2022
- ArticleRubens RD, Begent RH, Knight RK, Sexton SA, Hayward JL.Cancer. 1978 Oct;42(4):1680-6.Sixty-nine patients with advanced breast cancer treated with cytotoxic chemotherapy were randomized to receive concomitantly either norethisterone acetate (progestogen group) or a placebo (placebo group). Objective responses were seen in 53% of patients in the progestogen group and 61% of patients in the placebo group. The median duration of response was the same for both groups (38 weeks). Three out of ten patients in the placebo group, who received subsequently the progestogen on relapse, had a further objective regression. The overall survival in the two groups was similar, although in a sub-group of patients who had operable tumors, but a subsequent short disease-free interval, survival was significantly better in the placebo group. There was less myelosuppression in the progestogen group, who were able to receive higher doses of cytotoxic drugs. Less nausea and vomiting occurred in the progestogen group, but subjective side effects were similar. It is concluded that there is no advantage therapeutically in combining cytotoxic chemotherapy and progestogen therapy and, in some patients, better results are obtained using the two treatments sequentially.